Published in Cancer Weekly, December 23rd, 2003
CLT is an antifungal drug that has demonstrated anticancer activity but, its potential is limited by the presence of high liver toxicity. The goal of the study was to develop a variation or analogue of CLT that maintained the anticancer activity without the toxic side effects.
The results appear in an article entitled, "NC 381, A Novel Anti-cancer Agent, Arrests the Cell Cycle in G0 -G1 and Inhibits Lung Tumor Cell Growth In Vitro and In Vivo" in a November electronic version of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.